Acoustic Tumor Therapy: HIFU, FUS, and Histotripsy
Educational note: acoustic therapies are device- and indication-specific. Do not generalize one approval to all tumors.
TL;DR
Acoustic oncology uses focused ultrasound or related mechanical energy to heat tissue, mechanically disrupt tissue, open barriers, or support drug delivery. Some device indications are established; many cancer uses remain investigational.
Maturity Map
| Approach | Current footing |
|---|---|
| MR-guided focused ultrasound for bone metastasis pain | FDA PMA approval exists for palliation of pain from bone metastases after failed or unsuitable radiation |
| Histotripsy for liver tumors | FDA de novo authorization exists for non-invasive mechanical destruction of liver tumors |
| HIFU in prostate and other organs | Used in selected local contexts; indication and regulatory status vary by country/device |
| BBB opening and sonoporation | Mostly clinical research and translational work |
| Sonodynamic therapy | Early research; not routine oncology care |
Main Mechanisms
- Thermal ablation: focused energy heats tissue enough to cause coagulative necrosis.
- Histotripsy: pulsed ultrasound creates cavitation that mechanically disrupts tissue without relying on heat.
- Barrier opening/sonoporation: ultrasound and microbubbles transiently increase permeability.
- Sonodynamic therapy: ultrasound activates a sensitizer to generate reactive species; still early in oncology.
Key Caveats
- Acoustic windows matter: bone, gas, motion, and body habitus can block or distort treatment.
- Imaging and dosimetry are part of the therapy, not optional accessories.
- Local tumor control is not the same as systemic disease control.
- Combination claims with immunotherapy or chemotherapy should be labeled as investigational unless tied to a specific approval.
What Technologists Can Build
- Treatment-planning simulations with patient-specific anatomy.
- Real-time cavitation or temperature monitoring pipelines.
- Device logs linked to imaging and outcomes.
- Registries that separate local control, symptoms, toxicity, and survival.
References
- U.S. Food and Drug Administration. DEN220087: Edison Histotripsy System decision summary. https://www.accessdata.fda.gov/cdrh_docs/reviews/DEN220087.pdf
- U.S. Food and Drug Administration. Premarket Approval P110039: ExAblate MRgFUS. https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=P110039
- Bachu VS, Kedda J, Suk I, Green JJ, Tyler B. High-Intensity Focused Ultrasound: A Review of Mechanisms and Clinical Applications. Annals of Biomedical Engineering. 2021;49:1975-1991. PMID: 34374945. https://doi.org/10.1007/s10439-021-02833-9
- National Cancer Institute. Clinical trial phases. https://www.cancer.gov/about-cancer/treatment/clinical-trials/what-are-trials/phases